Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUDRACT2007-002409-36 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight weeks compared with A5 (b) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is not inferior in reducing blood pressure at eight weeks compared with A10 and (c) to demonstrate that the incidence of oedema on the fixed-dose combination T40/A5 pooled with the fixed-dose combination T80/A5 is superior (less oedema) to A10 in patients who fail to respond adequately to six weeks treatment with A5.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| fixed dose combination of telmisartan+amlodipine | Drug | |||
| amlodipine | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) | Change from baseline to the end of study in trough DBP | End of study (8 weeks or last value on treatment) |
| Number of Patients With Oedema | Patients from the treated set who experienced at least one case of general oedema. | During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) | Change from baseline to the end of study in trough SBP | End of study (8 weeks or last value on treatment) |
| Trough Seated Diastolic Blood Pressure Control |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 1235.5.32004 Boehringer Ingelheim Investigational Site | Aywaille | Belgium | ||||
| 1235.5.32001 Boehringer Ingelheim Investigational Site |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
1487 were enrolled, 1098 entered but 1 patient not treated.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Amlodipine 5mg | |
| FG001 | Amlodipine 10mg | |
| FG002 | Telmisartan 40mg and Amlodipine 5mg |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The number of patients who reach the target DBP of <90mmHg
| End of study (8 weeks or last value on treatment) |
| Trough Seated DBP Response | The number of patients who reach the target DBP of <90mmHg or had a reduction in DBP >= 10mmHg | End of study (8 weeks or last value on treatment) |
| Trough Seated SBP Control | The number of patients who reach the target SBP of <140mmHg | End of study (8 weeks or last value on treatment) |
| Trough Seated SBP Response | The number of patients who reach the target SBP of <140mmHg or had a reduction in SBP >= 15 mmHg | End of study (8 weeks or last value on treatment) |
| Trough Seated Blood Pressure (BP) Normality Classes | The number of patients who reach predefined BP categories:
| End of study (8 weeks or last value on treatment) |
| Brussels |
| Belgium |
| 1235.5.32010 Boehringer Ingelheim Investigational Site | Gozée | Belgium |
| 1235.5.32008 Boehringer Ingelheim Investigational Site | Linkebeek | Belgium |
| 1235.5.32003 Boehringer Ingelheim Investigational Site | Mol | Belgium |
| 1235.5.32007 Boehringer Ingelheim Investigational Site | Natoye | Belgium |
| 1235.5.32009 Boehringer Ingelheim Investigational Site | Tavier | Belgium |
| 1235.5.32002 Boehringer Ingelheim Investigational Site | Tienen-Kumtich | Belgium |
| 1235.5.32005 Boehringer Ingelheim Investigational Site | Turnhout | Belgium |
| 1235.5.20001 Boehringer Ingelheim Investigational Site | Coquitlam | British Columbia | Canada |
| 1235.5.20011 Boehringer Ingelheim Investigational Site | Vancouver | British Columbia | Canada |
| 1235.5.20007 Boehringer Ingelheim Investigational Site | Bay Roberts | Newfoundland and Labrador | Canada |
| 1235.5.20005 Boehringer Ingelheim Investigational Site | Mount Pearl | Newfoundland and Labrador | Canada |
| 1235.5.20008 Boehringer Ingelheim Investigational Site | St. John's | Newfoundland and Labrador | Canada |
| 1235.5.20013 Boehringer Ingelheim Investigational Site | Corunna | Ontario | Canada |
| 1235.5.20014 Boehringer Ingelheim Investigational Site | Etobicoke | Ontario | Canada |
| 1235.5.20010 Boehringer Ingelheim Investigational Site | Hamilton | Ontario | Canada |
| 1235.5.20012 Boehringer Ingelheim Investigational Site | London | Ontario | Canada |
| 1235.5.20009 Boehringer Ingelheim Investigational Site | Ottawa | Ontario | Canada |
| 1235.5.20006 Boehringer Ingelheim Investigational Site | Sarnia | Ontario | Canada |
| 1235.5.20003 Boehringer Ingelheim Investigational Site | Sainte-Foy | Quebec | Canada |
| 1235.5.45002 Boehringer Ingelheim Investigational Site | Birkerød | Denmark |
| 1235.5.45005 Boehringer Ingelheim Investigational Site | Haderslev | Denmark |
| 1235.5.45008 Boehringer Ingelheim Investigational Site | Herning | Denmark |
| 1235.5.45009 Boehringer Ingelheim Investigational Site | Hinnerup | Denmark |
| 1235.5.45001 Boehringer Ingelheim Investigational Site | Rødovre Municipality | Denmark |
| 1235.5.45006 Boehringer Ingelheim Investigational Site | Rødovre Municipality | Denmark |
| 1235.5.45003 Boehringer Ingelheim Investigational Site | Vaerløse | Denmark |
| 1235.5.45007 Boehringer Ingelheim Investigational Site | Vildbjerg | Denmark |
| 1235.5.35003 Boehringer Ingelheim Investigational Site | Joensuu | Finland |
| 1235.5.35004 Boehringer Ingelheim Investigational Site | Joensuu | Finland |
| 1235.5.35001 Boehringer Ingelheim Investigational Site | Turku | Finland |
| 1235.5.35002 Boehringer Ingelheim Investigational Site | Turku | Finland |
| 1235.5.3301H Boehringer Ingelheim Investigational Site | Aigrefeuille S/Maine | France |
| 1235.5.3306C Boehringer Ingelheim Investigational Site | Angers | France |
| 1235.5.3309B Boehringer Ingelheim Investigational Site | Angers | France |
| 1235.5.3309C Boehringer Ingelheim Investigational Site | Angers | France |
| 1235.5.3309E Boehringer Ingelheim Investigational Site | Angers | France |
| 1235.5.3309D Boehringer Ingelheim Investigational Site | Avrillé | France |
| 1235.5.3309A Boehringer Ingelheim Investigational Site | Beaucouzé | France |
| 1235.5.3303B Boehringer Ingelheim Investigational Site | Bono | France |
| 1235.5.3305A Boehringer Ingelheim Investigational Site | Bourg Des Cptes | France |
| 1235.5.3306D Boehringer Ingelheim Investigational Site | Briollay | France |
| 1235.5.3308B Boehringer Ingelheim Investigational Site | Cholet | France |
| 1235.5.3308C Boehringer Ingelheim Investigational Site | Cholet | France |
| 1235.5.3308D Boehringer Ingelheim Investigational Site | Cholet | France |
| 1235.5.3308F Boehringer Ingelheim Investigational Site | Cholet | France |
| 1235.5.3302C Boehringer Ingelheim Investigational Site | Garchizy | France |
| 1235.5.3303C Boehringer Ingelheim Investigational Site | Grandchamps | France |
| 1235.5.3302D Boehringer Ingelheim Investigational Site | Guérigny | France |
| 1235.5.3310A Boehringer Ingelheim Investigational Site | Jarny | France |
| 1235.5.3301L Boehringer Ingelheim Investigational Site | La Chapelle /s Erdre | France |
| 1235.5.3301J Boehringer Ingelheim Investigational Site | La Chapelle-sur-Erdre | France |
| 1235.5.3304A Boehringer Ingelheim Investigational Site | La Fresnais | France |
| 1235.5.3308E Boehringer Ingelheim Investigational Site | La Jubaudière | France |
| 1235.5.3301G Boehringer Ingelheim Investigational Site | La Montagne | France |
| 1235.5.3307D Boehringer Ingelheim Investigational Site | Le Mesnil-en-Vallée | France |
| 1235.5.3301E Boehringer Ingelheim Investigational Site | Le Temple-de-Bretagne | France |
| 1235.5.3309F Boehringer Ingelheim Investigational Site | Les Ponts-de-Cé | France |
| 1235.5.3307G Boehringer Ingelheim Investigational Site | Loudun | France |
| 1235.5.3305B Boehringer Ingelheim Investigational Site | Louvigné Le Bais | France |
| 1235.5.3307E Boehringer Ingelheim Investigational Site | Mouliherne | France |
| 1235.5.3306A Boehringer Ingelheim Investigational Site | Mûrs-Erigné | France |
| 1235.5.3307A Boehringer Ingelheim Investigational Site | Mûrs-Erigné | France |
| 1235.5.3301A Boehringer Ingelheim Investigational Site | Nantes | France |
| 1235.5.3301B Boehringer Ingelheim Investigational Site | Nantes | France |
| 1235.5.3301D Boehringer Ingelheim Investigational Site | Nantes | France |
| 1235.5.3301M Boehringer Ingelheim Investigational Site | Nantes | France |
| 1235.5.3302A Boehringer Ingelheim Investigational Site | Nevers | France |
| 1235.5.3302F Boehringer Ingelheim Investigational Site | Nevers | France |
| 1235.5.3301I Boehringer Ingelheim Investigational Site | Nort-sur-Erdre | France |
| 1235.5.3301C Boehringer Ingelheim Investigational Site | Orvault | France |
| 1235.5.3307F Boehringer Ingelheim Investigational Site | Parçay-les-Pins | France |
| 1235.5.3301F Boehringer Ingelheim Investigational Site | Saint Aubin Les Châteaux | France |
| 1235.5.3306F Boehringer Ingelheim Investigational Site | Saint-Georges-de-Montaigu | France |
| 1235.5.3304B Boehringer Ingelheim Investigational Site | Saint-Ouen-la-Rouërie | France |
| 1235.5.3307C Boehringer Ingelheim Investigational Site | Saint-Pierre-Montlimart | France |
| 1235.5.3301N Boehringer Ingelheim Investigational Site | Sautron | France |
| 1235.5.3306B Boehringer Ingelheim Investigational Site | Segré | France |
| 1235.5.3306E Boehringer Ingelheim Investigational Site | Thouars | France |
| 1235.5.3304C Boehringer Ingelheim Investigational Site | Tinténiac | France |
| 1235.5.3303A Boehringer Ingelheim Investigational Site | Vannes | France |
| 1235.5.3308A Boehringer Ingelheim Investigational Site | Vihiers | France |
| 1235.5.31008 Boehringer Ingelheim Investigational Site | Beerzerveld | Netherlands |
| 1235.5.31006 Boehringer Ingelheim Investigational Site | Bennebroek | Netherlands |
| 1235.5.31004 Boehringer Ingelheim Investigational Site | Hoogwoud | Netherlands |
| 1235.5.31003 Boehringer Ingelheim Investigational Site | Musselkanaal | Netherlands |
| 1235.5.31007 Boehringer Ingelheim Investigational Site | Nijverdal | Netherlands |
| 1235.5.31001 Boehringer Ingelheim Investigational Site | Oude Pekela | Netherlands |
| 1235.5.31005 Boehringer Ingelheim Investigational Site | Roelofarendsveen | Netherlands |
| 1235.5.31010 Boehringer Ingelheim Investigational Site | Voerendaal | Netherlands |
| 1235.5.47001 Boehringer Ingelheim Investigational Site | Ã…lesund | Norway |
| 1235.5.47002 Boehringer Ingelheim Investigational Site | Bergen | Norway |
| 1235.5.47003 Boehringer Ingelheim Investigational Site | Hamar | Norway |
| 1235.5.47004 Boehringer Ingelheim Investigational Site | Oslo | Norway |
| 1235.5.63006 Boehringer Ingelheim Investigational Site | Makati City | Philippines |
| 1235.5.63001 Boehringer Ingelheim Investigational Site | Manila | Philippines |
| 1235.5.63002 Boehringer Ingelheim Investigational Site | Manila | Philippines |
| 1235.5.63009 Boehringer Ingelheim Investigational Site | Manila | Philippines |
| 1235.5.63008 Boehringer Ingelheim Investigational Site | Pasay | Philippines |
| 1235.5.63005 Boehringer Ingelheim Investigational Site | Pasig | Philippines |
| 1235.5.63003 Boehringer Ingelheim Investigational Site | Quezon City | Philippines |
| 1235.5.63007 Boehringer Ingelheim Investigational Site | Quezon City | Philippines |
| 1235.5.27003 Boehringer Ingelheim Investigational Site | Boksburg | South Africa |
| 1235.5.27006 Boehringer Ingelheim Investigational Site | Cape Town | South Africa |
| 1235.5.27009 Boehringer Ingelheim Investigational Site | Cape Town | South Africa |
| 1235.5.27010 Boehringer Ingelheim Investigational Site | Cape Town | South Africa |
| 1235.5.27004 Boehringer Ingelheim Investigational Site | Durban | South Africa |
| 1235.5.27008 Boehringer Ingelheim Investigational Site | Johannesburg | South Africa |
| 1235.5.27001 Boehringer Ingelheim Investigational Site | Krugersdorp | South Africa |
| 1235.5.27005 Boehringer Ingelheim Investigational Site | Lenasia | South Africa |
| 1235.5.27002 Boehringer Ingelheim Investigational Site | Pretoria | South Africa |
| 1235.5.82007 Boehringer Ingelheim Investigational Site | Busan | South Korea |
| 1235.5.82001 Boehringer Ingelheim Investigational Site | Daegu | South Korea |
| 1235.5.82006 Boehringer Ingelheim Investigational Site | Daejeon | South Korea |
| 1235.5.82004 Boehringer Ingelheim Investigational Site | Gangwon-Do | South Korea |
| 1235.5.82008 Boehringer Ingelheim Investigational Site | Gwangju | South Korea |
| 1235.5.82002 Boehringer Ingelheim Investigational Site | Seoul | South Korea |
| 1235.5.82003 Boehringer Ingelheim Investigational Site | Seoul | South Korea |
| 1235.5.82005 Boehringer Ingelheim Investigational Site | Seoul | South Korea |
| 1235.5.46002 Boehringer Ingelheim Investigational Site | Gothenburg | Sweden |
| 1235.5.46003 Boehringer Ingelheim Investigational Site | Gothenburg | Sweden |
| 1235.5.46005 Boehringer Ingelheim Investigational Site | Luleå | Sweden |
| 1235.5.46004 Boehringer Ingelheim Investigational Site | Rättvik | Sweden |
| 1235.5.46001 Boehringer Ingelheim Investigational Site | Stockholm | Sweden |
| 1235.5.88605 Boehringer Ingelheim Investigational Site | Changhua | Taiwan |
| 1235.5.88608 Boehringer Ingelheim Investigational Site | Hualien City | Taiwan |
| 1235.5.88601 Boehringer Ingelheim Investigational Site | Kaohsiung City | Taiwan |
| 1235.5.88603 Boehringer Ingelheim Investigational Site | Taichung | Taiwan |
| FG003 | Telmisartan 80mg and Amlodipine 5mg |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Amlodipine 5mg | |
| BG001 | Amlodipine 10mg | |
| BG002 | Telmisartan 40mg and Amlodipine 5mg | |
| BG003 | Telmisartan 80mg and Amlodipine 5mg | |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) | Change from baseline to the end of study in trough DBP | Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Least Squares Mean | Standard Error | mmHg | End of study (8 weeks or last value on treatment) |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) | Change from baseline to the end of study in trough SBP | Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Least Squares Mean | Standard Error | mmHg | End of study (8 weeks or last value on treatment) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Trough Seated Diastolic Blood Pressure Control | The number of patients who reach the target DBP of <90mmHg | Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Number | patients | End of study (8 weeks or last value on treatment) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Trough Seated DBP Response | The number of patients who reach the target DBP of <90mmHg or had a reduction in DBP >= 10mmHg | Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Number | patients | End of study (8 weeks or last value on treatment) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Trough Seated SBP Control | The number of patients who reach the target SBP of <140mmHg | Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Number | patients | End of study (8 weeks or last value on treatment) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Trough Seated SBP Response | The number of patients who reach the target SBP of <140mmHg or had a reduction in SBP >= 15 mmHg | Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Number | patients | End of study (8 weeks or last value on treatment) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Trough Seated Blood Pressure (BP) Normality Classes | The number of patients who reach predefined BP categories:
| Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure | Posted | Number | patients | End of study (8 weeks or last value on treatment) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Patients With Oedema | Patients from the treated set who experienced at least one case of general oedema. | The treated set (TS) consisted of all patients that took at least one dose of the double-blind treatment (n=1097) | Posted | Number | patients | During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment) |
|
|
From day of first dose until one day after last dose
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Amlodipine 5mg | 2 | 267 | 22 | 267 | |||
| EG001 | Amlodipine 10mg | 1 | 276 | 74 | 276 | |||
| EG002 | Telmisartan 40mg and Amlodipine 5mg | 2 | 277 | 14 | 277 | |||
| EG003 | Telmisartan 80mg and Amlodipine 5mg | 1 | 277 | 10 | 277 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrilation | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chest discomfort | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chest pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Breast mass | Reproductive system and breast disorders | MedDRA 11.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Oedema peripheral | General disorders | MedDRA 11.0 | Systematic Assessment |
|
Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Boehringer Ingelheim Call Center | Boehringer Ingelheim Pharmaceuticals | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017311 | Amlodipine |
| ID | Term |
|---|---|
| D004095 | Dihydropyridines |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| Male |
|
Adjusted for baseline and country effect
| <0.0001 |
| Least Squares Mean Difference |
| -4.92 |
| Standard Error of the Mean |
| 0.64 |
| 95 |
| -6.18 |
| -3.66 |
| No |
| Superiority or Other |
| ANCOVA | Adjusted for baseline and country effect | Least Squares Mean Difference | -1.40 | Standard Error of the Mean | 0.64 | 95 | -2.66 | -0.14 | No | Superiority or Other |
| ANCOVA | Adjusted for baseline and country effect | Least Squares Mean Difference | -2.68 | Standard Error of the Mean | 0.64 | 95 | -3.93 | -1.43 | No | Superiority or Other |
|
|
|
|
|
| Participants |
|
|
|